Abstract 6P
Background
Development of an immunosuppressive pre-metastatic microenvironment is a prerequisite for lung metastasis of breast cancer. However, previous mechanisms have focused on immune cells rather than vascular endothelial cells. Our previous research has shown that tumor cell-released autophagosomes (TRAPs) preferentially reaches the lung rather than breast cancer cells in the mouse model. Could the pre-arrival of TRAPs promote the immunosuppressive pre-metastatic microenvironment by acting on endothelial cells?.
Methods
TRAPs-treated ECs were subjected to transcriptome analysis. T cell function was detected by flow cytometry after co-culture of TRAP-treated ECs with T cells in vitro. We injected TRAPs into mice via the tail vein or established endogenous Becn1 knockdown 4T1 tumor cells model which reduced TRAPs release. Flow cytometry will be used to analyze Immunosuppressive function of PVECs and the late lung metastases was monitored. Antibody blocking assay and HMGB1 knockdown cell lines were used to detect key DAMP on the surface of TRAPs. Inhibitor-treated ECs and TLR4 knockout mice were used to detect corresponding functional receptors on the surface of ECs. CD/FillpinⅢ/CPZ -treated ECs to detect the movement of the cytoskeleton. Activation of signal pathways was detected by Western blot.
Results
TRAPs from breast tumor cell lines stimulated the upregulation of PD-L1 in PVECs via a HMGB1-TLR4–MyD88–p38/STAT3 signal cascade and depended on the movement of the cytoskeleton of ECs. TRAPs-treated ECs suppressed IFN-γ secretion and proliferation of CD4+ and CD8+ T cells in vitro and in vivo. Anti-PD-L1 treatment upregulated pulmonary T-cell function and reduced lung metastasis in tumor-bearing mice.
Conclusions
These findings elucidate a novel role and mechanism of TRAPs-induced immunosuppression of vascular endothelial cells in the pre-metastatic microenvironment. TRAPs or their surface HMGB1 represent important therapeutic targets to reverse immunosuppressive formation, while also providing a new theoretical basis for the treatment of early breast cancer with PD-L1 antibodies.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Y. Wu, X. Zhou, C. Wu.
Funding
National Natural Science Foundation, China.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
519P - Final results and subgroup analysis of ORIENTAL: A phase IIIB study of durvalumab plus platinum-etoposide in first-line treatment of Chinese patients with extensive-stage small-cell lung cancer (ES-SCLC)
Presenter: Ying Cheng
Session: Poster Display
Resources:
Abstract
520P - Role of atezolizumab in controlling CNS progression in ES-SCLC
Presenter: Yoon Namgung
Session: Poster Display
Resources:
Abstract
521P - Camrelizumab combined with chemotherapy and apatinib as first-line therapy for extensive-stage small cell lung cancer: A phase II, single-arm, exploratory research
Presenter: Yanbin Zhao
Session: Poster Display
Resources:
Abstract
522P - Durvalumab plus etoposide and carboplatin for extensive-stage small cell lung cancer with mild idiopathic interstitial pneumonia
Presenter: Ichiro Nakachi
Session: Poster Display
Resources:
Abstract
523P - Camrelizumab plus apatinib as maintenance treatment in patients with extensive-stage small cell lung cancer who were responding or stable after standard first-line chemotherapy (CAMERA): Results from a single-arm, phase II trial
Presenter: Qi Wang
Session: Poster Display
Resources:
Abstract
524P - Treatment pattern and overall survival by lines of therapy among patients with advanced small cell lung cancer in Taiwan
Presenter: Kelly Huang
Session: Poster Display
Resources:
Abstract
525P - Development of diagnostic prediction score for malignant pleural effusion in lung cancer: MPE-Lung score
Presenter: Chaichana Chantharakhit
Session: Poster Display
Resources:
Abstract
526P - Burden and trends of tracheal, bronchus, and lung (TBL) cancer in Southeast Asia, East Asia, and Oceania from 1990-2019, and its projection of deaths to 2040: A benchmarking analysis
Presenter: Monika Chhayani
Session: Poster Display
Resources:
Abstract
527P - Efficacy of intraventricular chemotherapy with pemetrexed for leptomeningeal metastasis from lung adenocarcinoma: A retrospective study
Presenter: Fang Cun
Session: Poster Display
Resources:
Abstract
528P - Socioeconomic determinants of access to standard-of-care treatments in advanced and metastatic NSCLC in Hong Kong: A territory-wide study
Presenter: Ka Man Cheung
Session: Poster Display
Resources:
Abstract